SCHEMBL1553934

SCHEMBL1553934

COC(=O)c1ccc(OC)c(NC(=N)C(OC)c2ccccc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.57
NPSR1 Q6W5P4 4/20 0.57
L3MBTL1 Q9Y468 3/20 0.57
GAA P10253 2/20 0.53
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
POLB P06746 2/20 0.49
LMNA P02545 2/20 0.49
HDAC1 Q13547 3/20 0.48
HDAC8 Q9BY41 3/20 0.48
HDAC6 Q9UBN7 3/20 0.48
MAPK1 P28482 1/20 0.47
MAPT P10636 5/20 0.44
HTT P42858 1/20 0.44
LTB4R Q15722 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1553818 0.87 KMT2A (0.51) ALDH1A1NPSR1L3MBTL1GAAKMT2A
SCHEMBL4846737 0.82 HDAC1 (0.48) ALDH1A1NPSR1L3MBTL1GAAKMT2A
SCHEMBL1553849 0.82 ALDH1A1 (0.50) ALDH1A1NPSR1L3MBTL1GAAKMT2A
Hydrochloric Acid SCHEMBL1579963 0.81 HDAC1 (0.56) ALDH1A1NPSR1GAAKMT2AMEN1
SCHEMBL1554573 0.81 NPSR1 (0.47) ALDH1A1NPSR1L3MBTL1GAAKMT2A
SCHEMBL1553365 0.81 ALDH1A1 (0.52) ALDH1A1GAAKMT2AMEN1POLB
SCHEMBL1554111 0.80 HDAC1 (0.58) ALDH1A1NPSR1GAAKMT2AMEN1
SCHEMBL1553794 0.79 HDAC1 (0.45) ALDH1A1NPSR1KMT2AMEN1POLB
SCHEMBL1553674 0.79 NPSR1 (0.57) ALDH1A1NPSR1L3MBTL1KMT2AMEN1
SCHEMBL13425100 0.76 MAPT (0.58) ALDH1A1L3MBTL1GAAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0934307-B1 SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE AVENTIS PHARMA LTD (GB) 2011-04-27 EP disclosed
EP-2223920-A2 Substituted azabicyclic compounds Aventis Pharma Limited (GB) 2010-09-01 EP disclosed
US-7329675-B2 Substituted azabicyclic compounds AVENTIS PHARMA LIMITED (GB) 2008-02-12 US disclosed
US-20050038069-A1 Substituted azabicyclic compounds AVENTIS PHARMA LIMITED (GB) 2005-02-17 US disclosed
US-6800645-B1 INHIBIT PRODUCTION OR PHYSIOLOGICAL EFFECTS OF TNF, INHIBIT CYCLIC AMP PHOSPHODIESTERASE AVENTIS PHARMA LIMITED (GB) 2004-10-05 US disclosed
US-20020173527-A1 Substituted azabicyclic compounds ASTLES PETER CHARLES (GB) 2002-11-21 US disclosed
US-6303600-B1 USED IN THERAPY OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY RHONE-POULENC RORER LIMITED (GB) 2001-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173527-A1 Substituted azabicyclic compounds CBR1, NOX1, POR ALDH1A1 375/4885NPSR1 43/4885L3MBTL1 4122/4885
US-20050038069-A1 Substituted azabicyclic compounds NR2C2, NR3C1, NR3C2 ALDH1A1 2795/4885NPSR1 192/4885L3MBTL1 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.